Benchmark Reaffirms Buy Rating for Biofrontera (NASDAQ:BFRI)

Benchmark reaffirmed their buy rating on shares of Biofrontera (NASDAQ:BFRI) in a report issued on Friday, Benzinga reports. Benchmark currently has a $7.00 price target on the stock.

Biofrontera Stock Performance

Shares of BFRI opened at $1.36 on Friday. Biofrontera has a fifty-two week low of $0.61 and a fifty-two week high of $9.70. The firm’s 50-day simple moving average is $1.05 and its two-hundred day simple moving average is $1.20. The stock has a market cap of $6.92 million, a PE ratio of -0.10 and a beta of 0.46.

Institutional Trading of Biofrontera

An institutional investor recently bought a new position in Biofrontera stock. Rosalind Advisors Inc. bought a new position in Biofrontera Inc. (NASDAQ:BFRI) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 504,261 shares of the company’s stock, valued at approximately $777,000. Biofrontera makes up approximately 0.7% of Rosalind Advisors Inc.’s portfolio, making the stock its 27th biggest holding. Rosalind Advisors Inc. owned 9.91% of Biofrontera at the end of the most recent quarter. Institutional investors own 10.08% of the company’s stock.

Biofrontera Company Profile

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.